{"success":true,"data":{"pressRelease":{"id":"129572","rtpr_id":"nPn5yS9fHa","ticker":"REGN","exchange":"NASDAQ","all_tickers":["REGN"],"title":"REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline","author":"PR Newswire","published_at":"2026-08-27T14:09:00.415Z","article_body":"REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline\n\nPR Newswire\n\nNEW YORK, Aug. 27, 2026\n\nControl-person liability allegations focus on Regeneron executives' alleged\nauthority over public clinical-trial statements and SEC disclosures as REGN\nshares fell $102.09 from the Class Period high.\n\nNEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action\nhas been filed on behalf of shareholders who purchased Regeneron securities\nbetween August 1, 2025 and May 15, 2026. Find out if you may qualify to\nrecover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760319-14&h=3759933206&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195033%26wire%3D4&a=Find+out+if+you+may+qualify+to+recover+losses)\n. Questions may be directed to Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nREGN declined from a Class Period high of $731.77 on April 28, 2026 to $629.68\nafter the May 15, 2026 announcement, a decline of $102.09 per share, or\napproximately 13.95%. The window to apply for lead plaintiff closes on\nSeptember 14, 2026.\n\nCEO and Senior Officer Securities Liability Section 20(a) Control Person\nAllegations\n\nThe complaint names Regeneron and individual defendants George D. Yancopoulos,\nCo-Founder, President, Chief Executive Officer and Co-Chairman, Israel Lowy,\nSenior Vice President and Clinical Development Unit Head of Oncology, and Ryan\nCrowe, Senior Vice President of Investor Relations and Strategic Analysis. The\npleading asserts that these individuals, because of their positions, allegedly\npossessed power and authority over Regeneron's SEC reports, press releases,\ninvestor presentations, and communications with analysts.\n\nAs averred, investors relied on Regeneron's disclosures concerning whether the\nPhase III Fianlimab-Libtayo Study could show statistically significant\nimprovement in progression-free survival. The action claims that public\nstatements allegedly minimized the risk that slowing event accrual reflected\nflawed assumptions or insufficient clinical differentiation.\n\nAlleged Control Person Liability Points for REGN Shareholders\n\n * The complaint alleges the individual defendants possessed material non-public\ninformation about the Phase III Fianlimab-Libtayo Study.\n * The complaint further alleges that the individual defendants action could\ninfluence or control statements made in SEC filings, earnings calls, press\nreleases, and conference presentations.\n * Plaintiffs contend the defendants allegedly created a favorable impression\nabout the trial while the risk of failure had materially increased.\n * The complaint points to April 29, 2026 protocol changes expanding patients\neligible for PFS analysis as a key event that raised investor concerns.\n * The May 15, 2026 announcement stated the Phase 3 trial did not reach\nstatistical significance for its primary PFS endpoint.\nWhy Accountability Allegations Matter to REGN Investors\n\nSection 20(a) control-person allegations focus on whether senior officers\nallegedly had practical authority over corporate disclosures that investors\nused to value REGN shares. In this case, plaintiffs allege that authority was\nmaterial because the challenged statements concerned a late-stage oncology\ntrial tied to expectations for Fianlimab-Libtayo in advanced melanoma.\n\nCorporate officers have a duty to ensure their companies' public statements\nare accurate and complete. In this case, the complaint alleges the authority\nto shape clinical-trial disclosures was relevant because investors were\nevaluating a Phase III melanoma study that later missed its primary PFS\nendpoint. -- Joseph E. Levi, Esq.\n\nSubmit your information here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760319-14&h=1922393548&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195033%26wire%3D4&a=Submit+your+information+here)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REGN Lawsuit\n\nQ: What is the REGN class action lawsuit about? A: A securities class action\nhas been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging\nmaterially false and misleading statements between August 1, 2025 and May 15,\n2026. Shares fell approximately 13.95% from the Class Period high after\nRegeneron disclosed a protocol change and later announced that the Phase 3\nFianlimab trial did not reach statistical significance for improvement in\nprogression-free survival.\n\nQ: Who may be eligible in the REGN investor lawsuit? A: Investors who\npurchased REGN stock or securities between August 1, 2025 and May 15, 2026 and\nsuffered financial losses may be eligible. Eligibility is based on purchase\ndate and documented losses, not on whether the investor still holds the\nshares.\n\nQ: How much did REGN stock drop? A: REGN shares declined from $731.77 on\nApril 28, 2026 to $629.68 after the May 15, 2026 disclosure, a decline of\n$102.09 per share, or approximately 13.95% from the Class Period high.\n\nQ: What court was the REGN class action filed in? A: The case was filed in\nthe United States District Court for the Southern District of New York and\nasserts claims under the federal securities laws.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the class. Lead plaintiffs\nare typically investors with significant documented losses and provide\noversight of the litigation on behalf of other class members.\n\nQ: What documents do I need to evaluate my REGN transaction history? A:\nBrokerage statements or trade confirmations showing purchase dates, share\nquantities, prices paid, and any subsequent sale dates and prices are\ntypically used to evaluate potential losses.\n\nQ: What if I already sold my REGN shares, can I still recover losses? A: Yes.\nEligibility is based on when the shares were purchased and whether the\ninvestor suffered losses. Investors who bought during the Class Period and\nsold at a loss may still be eligible to participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members do not appear in court or give testimony. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nQ: What does it cost me to participate? A: Securities class actions are\ngenerally handled on a contingency basis. There are no upfront fees, no\nretainer, and no out-of-pocket costs, and any attorneys' fees and expenses\nawarded to class counsel are subject to court approval.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/regn-deadline-suewallst-reminds-regeneron-pharmaceuticals-inc-investors-of-upcoming-securities-class-action-deadline-302861293.html\n(https://www.prnewswire.com/news-releases/regn-deadline-suewallst-reminds-regeneron-pharmaceuticals-inc-investors-of-upcoming-securities-class-action-deadline-302861293.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2913978\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn5yS9fHa","title":"REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline","author":"PR Newswire","ticker":"REGN","created":"2026-08-27T14:09:00.415Z","tickers":["REGN"],"exchange":"NASDAQ","article_body":"REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline\n\nPR Newswire\n\nNEW YORK, Aug. 27, 2026\n\nControl-person liability allegations focus on Regeneron executives' alleged\nauthority over public clinical-trial statements and SEC disclosures as REGN\nshares fell $102.09 from the Class Period high.\n\nNEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt notifies investors in\nRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action\nhas been filed on behalf of shareholders who purchased Regeneron securities\nbetween August 1, 2025 and May 15, 2026. Find out if you may qualify to\nrecover losses\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760319-14&h=3759933206&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195033%26wire%3D4&a=Find+out+if+you+may+qualify+to+recover+losses)\n. Questions may be directed to Joseph E. Levi, Esq. at jlevi@SueWallSt.com\n(mailto:jlevi@SueWallSt.com)  or (888) SueWallSt.\n\nREGN declined from a Class Period high of $731.77 on April 28, 2026 to $629.68\nafter the May 15, 2026 announcement, a decline of $102.09 per share, or\napproximately 13.95%. The window to apply for lead plaintiff closes on\nSeptember 14, 2026.\n\nCEO and Senior Officer Securities Liability Section 20(a) Control Person\nAllegations\n\nThe complaint names Regeneron and individual defendants George D. Yancopoulos,\nCo-Founder, President, Chief Executive Officer and Co-Chairman, Israel Lowy,\nSenior Vice President and Clinical Development Unit Head of Oncology, and Ryan\nCrowe, Senior Vice President of Investor Relations and Strategic Analysis. The\npleading asserts that these individuals, because of their positions, allegedly\npossessed power and authority over Regeneron's SEC reports, press releases,\ninvestor presentations, and communications with analysts.\n\nAs averred, investors relied on Regeneron's disclosures concerning whether the\nPhase III Fianlimab-Libtayo Study could show statistically significant\nimprovement in progression-free survival. The action claims that public\nstatements allegedly minimized the risk that slowing event accrual reflected\nflawed assumptions or insufficient clinical differentiation.\n\nAlleged Control Person Liability Points for REGN Shareholders\n\n * The complaint alleges the individual defendants possessed material non-public\ninformation about the Phase III Fianlimab-Libtayo Study.\n * The complaint further alleges that the individual defendants action could\ninfluence or control statements made in SEC filings, earnings calls, press\nreleases, and conference presentations.\n * Plaintiffs contend the defendants allegedly created a favorable impression\nabout the trial while the risk of failure had materially increased.\n * The complaint points to April 29, 2026 protocol changes expanding patients\neligible for PFS analysis as a key event that raised investor concerns.\n * The May 15, 2026 announcement stated the Phase 3 trial did not reach\nstatistical significance for its primary PFS endpoint.\nWhy Accountability Allegations Matter to REGN Investors\n\nSection 20(a) control-person allegations focus on whether senior officers\nallegedly had practical authority over corporate disclosures that investors\nused to value REGN shares. In this case, plaintiffs allege that authority was\nmaterial because the challenged statements concerned a late-stage oncology\ntrial tied to expectations for Fianlimab-Libtayo in advanced melanoma.\n\nCorporate officers have a duty to ensure their companies' public statements\nare accurate and complete. In this case, the complaint alleges the authority\nto shape clinical-trial disclosures was relevant because investors were\nevaluating a Phase III melanoma study that later missed its primary PFS\nendpoint. -- Joseph E. Levi, Esq.\n\nSubmit your information here\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760319-14&h=1922393548&u=https%3A%2F%2Fsuewallst.com%2Flawsuits%2Fregeneron-pharmaceuticals-inc-class-action-lawsuit-regn%3Fprid%3D195033%26wire%3D4&a=Submit+your+information+here)\n or call (888) SueWallSt.\n\nWHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi &\nKorsinsky LLP has established itself as a nationally-recognized securities\nlitigation firm that has secured hundreds of millions of dollars for aggrieved\nshareholders and built a track record of winning high-stakes cases. The firm\nhas extensive expertise representing investors in complex securities\nlitigation and a team of over 70 employees to serve our clients. For seven\nyears in a row, Levi & Korsinsky has ranked in ISS Securities Class Action\nServices' Top 50 Report as one of the top securities litigation firms in the\nUnited States.\n\nFrequently Asked Questions About the REGN Lawsuit\n\nQ: What is the REGN class action lawsuit about? A: A securities class action\nhas been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging\nmaterially false and misleading statements between August 1, 2025 and May 15,\n2026. Shares fell approximately 13.95% from the Class Period high after\nRegeneron disclosed a protocol change and later announced that the Phase 3\nFianlimab trial did not reach statistical significance for improvement in\nprogression-free survival.\n\nQ: Who may be eligible in the REGN investor lawsuit? A: Investors who\npurchased REGN stock or securities between August 1, 2025 and May 15, 2026 and\nsuffered financial losses may be eligible. Eligibility is based on purchase\ndate and documented losses, not on whether the investor still holds the\nshares.\n\nQ: How much did REGN stock drop? A: REGN shares declined from $731.77 on\nApril 28, 2026 to $629.68 after the May 15, 2026 disclosure, a decline of\n$102.09 per share, or approximately 13.95% from the Class Period high.\n\nQ: What court was the REGN class action filed in? A: The case was filed in\nthe United States District Court for the Southern District of New York and\nasserts claims under the federal securities laws.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is\nthe investor appointed by the court to represent the class. Lead plaintiffs\nare typically investors with significant documented losses and provide\noversight of the litigation on behalf of other class members.\n\nQ: What documents do I need to evaluate my REGN transaction history? A:\nBrokerage statements or trade confirmations showing purchase dates, share\nquantities, prices paid, and any subsequent sale dates and prices are\ntypically used to evaluate potential losses.\n\nQ: What if I already sold my REGN shares, can I still recover losses? A: Yes.\nEligibility is based on when the shares were purchased and whether the\ninvestor suffered losses. Investors who bought during the Class Period and\nsold at a loss may still be eligible to participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members do not appear in court or give testimony. If there\nis a settlement or recovery, eligible class members generally submit a claim\nform to seek their portion.\n\nQ: What does it cost me to participate? A: Securities class actions are\ngenerally handled on a contingency basis. There are no upfront fees, no\nretainer, and no out-of-pocket costs, and any attorneys' fees and expenses\nawarded to class counsel are subject to court approval.\n\nCONTACT:\n\nLevi & Korsinsky, LLP\n\nJoseph E. Levi, Esq.\n\n33 Whitehall Street, 27th Floor\n\nNew York, NY 10004\n\njlevi@SueWallSt.com (mailto:jlevi@SueWallSt.com)\n\nTel: (888) SueWallSt\n\nFax: (212) 363-7171\n\nAttorney Advertising. Prior results do not guarantee similar outcomes.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/regn-deadline-suewallst-reminds-regeneron-pharmaceuticals-inc-investors-of-upcoming-securities-class-action-deadline-302861293.html\n(https://www.prnewswire.com/news-releases/regn-deadline-suewallst-reminds-regeneron-pharmaceuticals-inc-investors-of-upcoming-securities-class-action-deadline-302861293.html)\n\nSOURCE SueWallSt.com\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1812443/suewallst-logo-1-Logo.jpg?id=OA2913978\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-27T14:09:00.47307518Z","server_sent_at_ms":1787839740473},"received_at":"2026-08-27T14:09:00.523Z","source_url":"https://www.prnewswire.com/news-releases/regn-deadline-suewallst-reminds-regeneron-pharmaceuticals-inc-investors-of-upcoming-securities-class-action-deadline-302861293.html"},"analysis":{"id":"118486","press_release_id":"129572","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"SueWallSt, powered by Levi & Korsinsky LLP, issued a reminder to Regeneron Pharmaceuticals investors regarding the upcoming lead plaintiff deadline for a securities class action lawsuit.\n\nThe complaint alleges control-person liability related to public statements about the Phase III Fianlimab-Libtayo study, following a roughly 14% share price decline after the trial failed to reach statistical significance.\n\nThis release is a plaintiff-law-firm solicitation for investors to seek counsel and does not constitute new corporate disclosure from Regeneron itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":null,"quotedText":"SueWallSt notifies investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a securities class action has been filed on behalf of shareholders who purchased Regeneron securities","namedEntities":{"people":[{"name":"George D. Yancopoulos","role":"Co-Founder, President, CEO and Co-Chairman"},{"name":"Israel Lowy","role":"Senior Vice President and Clinical Development Unit Head of Oncology"},{"name":"Ryan Crowe","role":"Senior Vice President of Investor Relations and Strategic Analysis"},{"name":"Joseph E. Levi","role":"Esq."}],"products":["Fianlimab","Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$102.09","context":"decline in share price from Class Period high"},{"amount":"$731.77","context":"Class Period high share price on April 28, 2026"},{"amount":"$629.68","context":"share price after May 15, 2026 announcement"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by SueWallSt/Levi & Korsinsky. This is a reminder regarding a lead plaintiff deadline and does not represent new disclosure from Regeneron. No court certification or settlement amount is announced."},"tickerRelevance":{"others":[],"primary":"REGN"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"SueWallSt, powered by Levi & Korsinsky LLP, issued a reminder to Regeneron Pharmaceuticals investors regarding the upcoming lead plaintiff deadline for a securities class action lawsuit.\n\nThe complaint alleges control-person liability related to public statements about the Phase III Fianlimab-Libtayo study, following a roughly 14% share price decline after the trial failed to reach statistical significance.\n\nThis release is a plaintiff-law-firm solicitation for investors to seek counsel and does not constitute new corporate disclosure from Regeneron itself.","key_figures":null,"named_entities":{"people":[{"name":"George D. Yancopoulos","role":"Co-Founder, President, CEO and Co-Chairman"},{"name":"Israel Lowy","role":"Senior Vice President and Clinical Development Unit Head of Oncology"},{"name":"Ryan Crowe","role":"Senior Vice President of Investor Relations and Strategic Analysis"},{"name":"Joseph E. Levi","role":"Esq."}],"products":["Fianlimab","Libtayo"],"companies":[{"name":"Regeneron Pharmaceuticals, Inc.","ticker":"REGN"},{"name":"Levi & Korsinsky LLP","relationship":"plaintiff law firm"},{"name":"SueWallSt","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$102.09","context":"decline in share price from Class Period high"},{"amount":"$731.77","context":"Class Period high share price on April 28, 2026"},{"amount":"$629.68","context":"share price after May 15, 2026 announcement"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T16:03:33.264Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"large-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":134953,"modelName":"glm-4.7"}}